AU2021356692A1 - Liver specific production of enpp1 or enpp3 - Google Patents

Liver specific production of enpp1 or enpp3 Download PDF

Info

Publication number
AU2021356692A1
AU2021356692A1 AU2021356692A AU2021356692A AU2021356692A1 AU 2021356692 A1 AU2021356692 A1 AU 2021356692A1 AU 2021356692 A AU2021356692 A AU 2021356692A AU 2021356692 A AU2021356692 A AU 2021356692A AU 2021356692 A1 AU2021356692 A1 AU 2021356692A1
Authority
AU
Australia
Prior art keywords
enpp1
subject
polypeptide
nucleic acid
viral vector
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021356692A
Other languages
English (en)
Other versions
AU2021356692A9 (en
Inventor
Demetrios Braddock
Steven Jungles
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yale University
Biomarin Pharmaceutical Inc
Original Assignee
Yale University
Inozyme Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yale University, Inozyme Pharma Inc filed Critical Yale University
Publication of AU2021356692A1 publication Critical patent/AU2021356692A1/en
Publication of AU2021356692A9 publication Critical patent/AU2021356692A9/en
Assigned to YALE UNIVERSITY, BIOMARIN PHARMACEUTICAL INC. reassignment YALE UNIVERSITY Request for Assignment Assignors: INOZYME PHARMA, INC., YALE UNIVERSITY
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/04—Phosphoric diester hydrolases (3.1.4)
    • C12Y301/04001—Phosphodiesterase I (3.1.4.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y306/00—Hydrolases acting on acid anhydrides (3.6)
    • C12Y306/01—Hydrolases acting on acid anhydrides (3.6) in phosphorus-containing anhydrides (3.6.1)
    • C12Y306/01009—Nucleotide diphosphatase (3.6.1.9), i.e. nucleotide-pyrophosphatase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14171—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Virology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2021356692A 2020-10-08 2021-10-08 Liver specific production of enpp1 or enpp3 Pending AU2021356692A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063089515P 2020-10-08 2020-10-08
US63/089,515 2020-10-08
US202163165650P 2021-03-24 2021-03-24
US63/165,650 2021-03-24
US202163248339P 2021-09-24 2021-09-24
US63/248,339 2021-09-24
PCT/US2021/054216 WO2022076848A1 (en) 2020-10-08 2021-10-08 Liver specific production of enpp1 or enpp3

Publications (2)

Publication Number Publication Date
AU2021356692A1 true AU2021356692A1 (en) 2023-05-04
AU2021356692A9 AU2021356692A9 (en) 2024-06-13

Family

ID=81126156

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021356692A Pending AU2021356692A1 (en) 2020-10-08 2021-10-08 Liver specific production of enpp1 or enpp3

Country Status (7)

Country Link
US (1) US20240148907A1 (https=)
EP (1) EP4225927A4 (https=)
JP (1) JP2023548758A (https=)
AU (1) AU2021356692A1 (https=)
CA (1) CA3195071A1 (https=)
TW (1) TW202229557A (https=)
WO (1) WO2022076848A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023049864A1 (en) * 2021-09-24 2023-03-30 Inozyme Pharma, Inc. Lyophilized enpp1 polypeptide formulations and uses thereof
CN119242712A (zh) * 2024-09-27 2025-01-03 南京师范大学 特异性靶向骨骼肌细胞的携带miRNA-486基因的腺相关病毒载体、药物组合物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1736553A1 (en) * 2005-06-17 2006-12-27 Centre National De La Recherche Scientifique ENPP1 (PC-1) gene haplotype associated with the risk of obesity and type 2 diabetes and their applications
CA2788682C (en) * 2010-02-05 2019-03-05 The University Of North Carolina At Chapel Hill Compositions and methods for enhanced parvovirus transduction
WO2014126965A2 (en) * 2013-02-13 2014-08-21 Yale University Compositions and methods for treating pathological calcification and ossification
KR20250078598A (ko) * 2015-05-19 2025-06-02 예일 유니버시티 병리학적 석회화 병태를 치료하기 위한 조성물, 및 이의 사용 방법
WO2017087936A1 (en) * 2015-11-20 2017-05-26 Yale University Compositions for treating ectopic calcification disorders, and methods using same
KR20210142599A (ko) * 2019-01-18 2021-11-25 이노자임 파마, 인코포레이티드 Enpp1 또는 enpp3 결핍을 수반하는 질환의 치료

Also Published As

Publication number Publication date
US20240148907A1 (en) 2024-05-09
AU2021356692A9 (en) 2024-06-13
EP4225927A1 (en) 2023-08-16
WO2022076848A1 (en) 2022-04-14
JP2023548758A (ja) 2023-11-21
CA3195071A1 (en) 2022-04-14
EP4225927A4 (en) 2025-05-07
TW202229557A (zh) 2022-08-01

Similar Documents

Publication Publication Date Title
US11766448B2 (en) Compositions and methods for altering tissue specificity and improving AAV9-mediated gene transfer
JP2022528416A (ja) 組換えアデノ随伴ウイルス及びその使用
JP7724156B2 (ja) Ｅｎｐｐ１またはｅｎｐｐ３の欠乏をともなう疾患の治療
AU2017322377B2 (en) Acid-alpha glucosidase variants and uses thereof
CN113316639A (zh) 用于治疗庞贝氏病的治疗性腺相关病毒
CN111902539A (zh) 杂合调控元件
KR20210021310A (ko) 코돈-최적화된 산 알파-글루코시다제 발현 카세트 및 이를 사용하는 방법
US20230322873A1 (en) Methods to produce rod-derived cone viability factor (rdcvf)
CA3119771A1 (en) Compositions and methods useful for targeting the blood-brain barrier
KR20220095183A (ko) 바이러스 감염을 치료하기 위한 조성물 및 방법
JP2022529680A (ja) 線維芽細胞増殖因子２３関連低リン血症性疾患の遺伝子療法
AU2021356692A1 (en) Liver specific production of enpp1 or enpp3
CN114555808A (zh) 嵌合多肽及其用途
JP7357039B2 (ja) 神経変性疾患、例えばとりわけ、パーキンソン病およびハンチントン病の治療における、ａａｖ／ｕｐｒ－プラスウイルス、ｕｐｒ－プラス融合たんぱく質、遺伝子治療、およびその使用
US20230064077A1 (en) Treatment of mucopolysaccharidosis iva
CN118871459A (zh) 新型蛋白质和核酸序列及其在预防和/或治疗先天性肌营养不良症中的用途
JP2024528997A (ja) 放射線誘発性唾液機能低下を予防するためのａｑｐ１遺伝子療法
WO2025132267A1 (en) Plasmids, transgenes, vectors and medical uses comprising tissue non-specific alkaline phosphatase
RU2780329C2 (ru) Варианты кислой альфа-глюкозидазы и их использование
US20250288693A1 (en) Insulin and glucokinase gene therapy compositions and its use for treating diabetes
RU2823353C2 (ru) КОДОН-ОПТИМИЗИРОВАННЫЕ ЭКСПРЕССИРУЮЩИЕ КАССЕТЫ КИСЛОЙ α-ГЛЮКОЗИДАЗЫ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
HK40059690A (en) Therapeutic adeno-associated virus for treating pompe disease
CN116669774A (zh) 用于治疗法布里病的组合物和方法
JPWO2022076848A5 (https=)

Legal Events

Date Code Title Description
SREP Specification republished
PC1 Assignment before grant (sect. 113)

Owner name: BIOMARIN PHARMACEUTICAL INC.

Free format text: FORMER APPLICANT(S): INOZYME PHARMA, INC.; YALE UNIVERSITY

Owner name: YALE UNIVERSITY

Free format text: FORMER APPLICANT(S): INOZYME PHARMA, INC.; YALE UNIVERSITY